Evidence map›Paper›PMID 40754007›Full record

ArticleJournal of virological methods2025

Limitations and use of the Morpheus-V5 dual reporter virus in assessing interventions that target HIV latency.

Kiho Tanaka, Youry Kim, Jesslyn Ong, Carolin Tumpach, Ajantha Rhodes, Hannah Ad King, Anna C Hearps, Michael Roche, Sharon R Lewin

Abstract read
In one paragraph

Article in Journal of virological methods, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kiho TanakaDepartment of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Youry KimDepartment of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Jesslyn OngDepartment of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Carolin TumpachDepartment of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Ajantha RhodesDepartment of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Hannah Ad KingDepartment of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Anna C HearpsDepartment of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia; Burnet Institute, Melbourne, Victoria, Australia; Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia.
Michael RocheDepartment of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia; Infectious and Inflammatory Diseases Theme, School of Health and Biomedical Sciences, RMIT University, Melbourne, Australia.
Sharon R LewinDepartment of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia; Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia; Victorian Infectious Diseases Service, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia. Electronic address: sharon.lewin@unimelb.edu.au.

Funding

Delaney AIDS Research Enterprise to Cure HIVUM1AI164560 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS, Sharon Ruth Lewin · 2021 to 2026
$32.0M
NIAID NIH HHS 1UM1AI164560–01NIAID NIH HHS UM1 AI164560
6 · The paper itself

Abstract

HIV can persist indefinitely in latently infected CD4 + T-cells as an integrated provirus with limited or no viral transcription and expression of viral proteins. We further characterised a recently described dual reporter virus, Morpheus-V5, that expresses murine heat-stable antigen and mCherry in productively infected cells (which is HIV LTR dependent) and V5 and Nerve growth factor receptor (NGFR) in latently infected cells (which is HIV LTR independent). We demonstrated successful infection of resting and activated CD4 + T-cells using Morpheus-V5 pseudotyped with either X4, R5 or dual tropic envelope proteins. We also showed that expression of NGFR (a transmembrane protein) enriched for infected cells (that contained HIV DNA) with inducible virus, however uninfected cells also expressed NGFR as a result of NGFR incorporation into virion preparations. Following treatment of CD4 + T-cells infected with Morpheus-V5 with latency reversal agents, we demonstrated an increase in the percentage of cells expressing mCherry and a decrease in the percentage of cells expressing NGFR. In addition, using this model, we showed that latent and productively infected cells had different levels of sensitivity to pro-apoptotic compounds. The Morpheus-V5 dual reporter virus has some limitations and overestimates the number of latently infected cells, but is a useful tool to investigate interventions that disrupt HIV latency.

Indexed as

CD4-Positive T-LymphocytesGenes, ReporterHIV-1Virus LatencyAnimalsCell LineHIV InfectionsHumansLuminescent ProteinsReceptors, Nerve Growth FactorRed Fluorescent ProteinLuminescent ProteinsReceptors, Nerve Growth FactorRed Fluorescent ProteinApoptosisCD4 +T-cellDual-reporterHIVLatencyLatency reversalMDM

Identifiers

PMID40754007
PMCPMC13283291

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.